<DOC>
	<DOCNO>NCT02514278</DOCNO>
	<brief_summary>Standard treatment rectal cancer rectal excision neoadjuvant radiochemotherapy . A new concept suggest organ preservation alternative rectal excision good responder neoadjuvant radiochemotherapy decrease surgical morbidity increase quality life . The rational fact 15 % patient sterilize tumour radiochemotherapy T3T4 rectal cancer . The French GRECCAR 2 trial first phase III trial investigate strategy : patient T2T3 low rectal carcinoma ( size ≤4 cm ) receive 50 Gy capecitabine good clinical responder ( ≤2 cm ) randomize local rectal excision . The main finding : rate complete pathologic response high radiochemotherapy small T2T3 T3T4 tumour ( 40 % vs 15 % ypT0 ) good pathologic responder ( ypT0-1 ) associate zero positive mesorectal node . The objective new trial increase proportion patient treat organ preservation optimize tumour response . As compare Folfiri , tritherapy Folfirinox show enhance response rate . In patient colorectal metastasis , response rate R0 resection twice high , result improve survival . Folfirinox also increase response chance R0 resection rate initially unresectable colorectal metastasis , compare standard intensify bi-chemotherapy regimen . Adding two month neoadjuvant chemotherapy ( Folfirinox ) radiochemotherapy , investigator expect increase chance organ preservation rate , compare radiochemotherapy alone .</brief_summary>
	<brief_title>Optimisation Response Organ Preservation Rectal Cancer : Neoadjuvant Chemotherapy Radiochemotherapy vs. Radiochemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Rectal adenocarcinoma cT2T3 cN01 ( ≤ 3 lymph node , size ≤8mm ) Tumour size ≤4 cm Location ≤10 cm anal verge No distant metastasis Patient ≥18 year ECOG ≤2 Effective contraception study Patient doctor sign informed consent T1 T4 Tumour size &gt; 4cm N2 ( &gt; 3 lymph node size &gt; 8mm ) Tumour &gt; 10 cm anal verge Distant metastasis Chronic intestinal inflammation and/or bowel obstruction Contra indication chemotherapy and/or radiotherapy Previous pelvic radiotherapy chemotherapy Severe renal , hepatic insufficiency ( serum creatinine &lt; 30ml/min ) Peripheral neuropathy &gt; grade 1 Dihydropyrimidine dehydrogenase deficiency Concomitant treatment millepertuis , yellow fever vaccine , phenytoin sorivudine ( chemically equivalent ) Pregnant breastfeed woman . Persons deprive liberty guardianship Impossibility compliance followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Organ preservation</keyword>
	<keyword>Local excision</keyword>
	<keyword>Radiochemotherapy</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>Folfirinox</keyword>
	<keyword>Tumour response</keyword>
</DOC>